Drug Trial Radar · NCT05499130
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
290
Actual
Start
Sep 30, 2022
Primary completion
Nov 12, 2024
Study completion Nov 12, 2024
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: * To evaluate the efficacy of 2 different doses of TEV-48574 as assessed by multiple standard measures * To evaluate the safety and tolerability of 2 different doses of TEV-48574 * To evaluate the immunogenicity of 2 different dioses of TEV-48574 The study will consist of a screening period of up to 6 weeks (42 days), a 14-week treatment period, and a 4-week follow-up period.
Conditions
- Crohn Disease
- Colitis, Ulcerative
Interventions
TEV-48574Drug
Subcutaneous infusion
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMSTime frame: Week 14
- Number of Participants With Moderate to Severe CD Who Showed an Endoscopic Response as Defined by the SES-CDTime frame: Baseline to Week 14
Locations
164 sites in 19 countries. Site status is shown where the registry gives one.
Teva Investigational Site 15568
Sun City, Arizona
Teva Investigational Site 15556
San Diego, California
Teva Investigational Site 15747
San Diego, California
Teva Investigational Site 15357
Kissimmee, Florida
Teva Investigational Site 15563
Miami, Florida
Teva Investigational Site 15365
Miami, Florida
Teva Investigational Site 15748
Miami, Florida
Teva Investigational Site 15375
Orlando, Florida
Teva Investigational Site 15359
Pinellas Park, Florida
Teva Investigational Site 15566
Glenview, Illinois
Teva Investigational Site 15567
Gurnee, Illinois
Teva Investigational Site 15574
New Albany, Indiana
Teva Investigational Site 15362
Iowa City, Iowa
Teva Investigational Site 15367
Kansas City, Kansas
Teva Investigational Site 15368
Louisville, Kentucky
Teva Investigational Site 15575
Louisville, Kentucky
Teva Investigational Site 15363
Columbia, Maryland
Teva Investigational Site 15358
Liberty, Missouri
Teva Investigational Site 15373
St Louis, Missouri
Teva Investigational Site 15369
Las Vegas, Nevada
Teva Investigational Site 15558
North Massapequa, New York
Teva Investigational Site 15370
Chapel Hill, North Carolina
Teva Investigational Site 15750
Beavercreek, Ohio
Teva Investigational Site 15557
Greenville, South Carolina
Teva Investigational Site 15573
Cordova, Tennessee
Teva Investigational Site 15360
Austin, Texas
Teva Investigational Site 15371
Dallas, Texas
Teva Investigational Site 15569
Garland, Texas
Teva Investigational Site 15559
Harlingen, Texas
Teva Investigational Site 15366
Katy, Texas
Teva Investigational Site 15743
Lubbock, Texas
Teva Investigational Site 15372
Pearland, Texas
Teva Investigational Site 15374
San Antonio, Texas
Teva Investigational Site 15565
Southlake, Texas
Teva Investigational Site 15361
Tyler, Texas
Teva Investigational Site 15364
Salt Lake City, Utah
Teva Investigational Site 33055
Innsbruck, Austria
Teva Investigational Site 33056
Vienna, Austria
Teva Investigational Site 37134
Edegem, Belgium
Teva Investigational Site 37133
Liège, Belgium
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.